Elizabeth Stoner

We are a biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Our scientific foundation is based on a deep understanding of immune biology and disease analytics. This work, together with our protein engineering and antibody design expertise has led to the development of a number of novel therapeutics for immune-mediated diseases with high unmet need.

iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com

Biotechnology, cell therapy, oncology, iNKT cell therapy, invariant natural killer T (iNKT) cell therapy platform, blood cancers, solid tumours, gastric & pancreatic cancers.

We are a biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.

MPM BioImpact is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. MPM BioImpact invests across the biotech landscape from early stage start-ups to public companies.

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Our scientific foundation is based on a deep understanding of immune biology and disease analytics. This work, together with our protein engineering and antibody design expertise has led to the development of a number of novel therapeutics for immune-mediated diseases with high unmet need.